Angela Alistar, MD
Gastrointestinal cancer researcher Angela Alistar, MD, has joined Atlantic Health System Cancer Care as Medical Director of GI Medical Oncology at Morristown Medical Center.
Dr. Alistar is a board-certified medical oncologist who specializes in translational research. She comes to Atlantic Health System from the Wake Forest School of Medicine, where she led the gastrointestinal oncology team, bringing cutting-edge treatments to patients. While there, she designed, secured funding for, and conducted five investigator-initiated therapeutic clinical trials and was the Principal Investigator of the Precision Oncology study, which is poised to generate new hypotheses in the era of genomic-driven clinical trials.
Dr. Alistar’s primary focus at Wake Forest School of Medicine was immuno-oncology and its application in treatment of cancers of the pancreas, colon, rectum, bile duct, and esophagus, as well as in melanoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genetics.
Dr. Alistar is a member of ASCO, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many other professional societies. She also serves as a member and advisor to several other health-care organizations. She is certified by the American Board of Internal Medicine, in both internal medicine and medical oncology.
Dr. Alistar received her medical degree from the University of Medicine and Pharmacy, Cluj Napoca, Romania, and conducted her internship and residency at Englewood Hospital and Medical Center, where she was Chief Resident. After her residency, she was a fellow in hematology and medical oncology at Mount Sinai School of Medicine, Tisch Cancer Institute. She currently serves as an ad hoc reviewer for JAMA and was recently the recipient of the Danny Danielson Translational Innovation Award for her dedication to clinical research.
Dr. Alistar will serve as the Co-Principal Investigator with Philip Philip, MD, PhD, FRCP, of Karmanos Cancer Center, on a planned multicenter phase II/III study of CPI-613 in combination with modified FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin) for metastatic pancreatic cancer. She has led four other clinical trials of CPI-613 for gastrointestinal cancers, as well as studies of other novel oncology drugs, and research to determine disease processes and genetic factors in cancers of the gastrointestinal tract. ■